Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free AAPG Stock Alerts

Ascentage Pharma Group International (AAPG) Competitors

Ascentage Pharma Group International logo
$19.84 +0.60 (+3.12%)
As of 01:31 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

AAPG vs. PTCT, COGT, SRRK, CNTA, and CGON

Should you buy Ascentage Pharma Group International stock or one of its competitors? MarketBeat compares Ascentage Pharma Group International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ascentage Pharma Group International include PTC Therapeutics (PTCT), Cogent Biosciences (COGT), Scholar Rock (SRRK), Centessa Pharmaceuticals (CNTA), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry.

How does Ascentage Pharma Group International compare to PTC Therapeutics?

Ascentage Pharma Group International (NASDAQ:AAPG) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

Ascentage Pharma Group International has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

In the previous week, PTC Therapeutics had 16 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 19 mentions for PTC Therapeutics and 3 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 0.76 beat PTC Therapeutics' score of 0.47 indicating that Ascentage Pharma Group International is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascentage Pharma Group International
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
PTC Therapeutics
8 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ascentage Pharma Group International has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. Ascentage Pharma Group International's return on equity of 0.00% beat PTC Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ascentage Pharma Group InternationalN/A N/A N/A
PTC Therapeutics -22.58%-362.45%-6.76%

PTC Therapeutics has higher revenue and earnings than Ascentage Pharma Group International.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascentage Pharma Group International$82.10M22.58-$177.71MN/AN/A
PTC Therapeutics$1.73B3.75$682.64M-$2.33N/A

Ascentage Pharma Group International currently has a consensus price target of $46.43, indicating a potential upside of 133.93%. PTC Therapeutics has a consensus price target of $91.57, indicating a potential upside of 17.05%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, equities research analysts plainly believe Ascentage Pharma Group International is more favorable than PTC Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20
PTC Therapeutics
2 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
2.80

Summary

Ascentage Pharma Group International beats PTC Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Cogent Biosciences?

Ascentage Pharma Group International (NASDAQ:AAPG) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Ascentage Pharma Group International presently has a consensus price target of $46.43, suggesting a potential upside of 133.93%. Cogent Biosciences has a consensus price target of $43.73, suggesting a potential upside of 11.21%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, research analysts plainly believe Ascentage Pharma Group International is more favorable than Cogent Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20
Cogent Biosciences
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.86

Ascentage Pharma Group International has higher revenue and earnings than Cogent Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascentage Pharma Group International$82.10M22.58-$177.71MN/AN/A
Cogent BiosciencesN/AN/A-$328.94M-$2.17N/A

In the previous week, Ascentage Pharma Group International and Ascentage Pharma Group International both had 3 articles in the media. Cogent Biosciences' average media sentiment score of 1.20 beat Ascentage Pharma Group International's score of 0.76 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascentage Pharma Group International
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cogent Biosciences
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ascentage Pharma Group International has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Ascentage Pharma Group International's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Ascentage Pharma Group InternationalN/A N/A N/A
Cogent Biosciences N/A -104.27%-54.64%

Summary

Ascentage Pharma Group International beats Cogent Biosciences on 6 of the 9 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Scholar Rock?

Ascentage Pharma Group International (NASDAQ:AAPG) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Ascentage Pharma Group International has higher revenue and earnings than Scholar Rock.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascentage Pharma Group International$82.10M22.58-$177.71MN/AN/A
Scholar RockN/AN/A-$377.94M-$3.59N/A

In the previous week, Ascentage Pharma Group International and Ascentage Pharma Group International both had 3 articles in the media. Scholar Rock's average media sentiment score of 1.14 beat Ascentage Pharma Group International's score of 0.76 indicating that Scholar Rock is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascentage Pharma Group International
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Scholar Rock
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ascentage Pharma Group International's return on equity of 0.00% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
Ascentage Pharma Group InternationalN/A N/A N/A
Scholar Rock N/A -163.52%-96.67%

Ascentage Pharma Group International has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Ascentage Pharma Group International currently has a consensus target price of $46.43, indicating a potential upside of 133.93%. Scholar Rock has a consensus target price of $56.00, indicating a potential upside of 3.75%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, analysts clearly believe Ascentage Pharma Group International is more favorable than Scholar Rock.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20
Scholar Rock
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
4 Strong Buy rating(s)
3.12

91.1% of Scholar Rock shares are held by institutional investors. 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Ascentage Pharma Group International and Scholar Rock tied by winning 6 of the 12 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Centessa Pharmaceuticals?

Ascentage Pharma Group International (NASDAQ:AAPG) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Ascentage Pharma Group International currently has a consensus target price of $46.43, indicating a potential upside of 133.93%. Centessa Pharmaceuticals has a consensus target price of $41.33, indicating a potential upside of 2.06%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, research analysts plainly believe Ascentage Pharma Group International is more favorable than Centessa Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20
Centessa Pharmaceuticals
1 Sell rating(s)
9 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.21

Ascentage Pharma Group International's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ascentage Pharma Group InternationalN/A N/A N/A
Centessa Pharmaceuticals N/A -60.37%-44.17%

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Ascentage Pharma Group International has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Ascentage Pharma Group International has higher revenue and earnings than Centessa Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascentage Pharma Group International$82.10M22.58-$177.71MN/AN/A
Centessa PharmaceuticalsN/AN/A-$197.53M-$1.79N/A

In the previous week, Ascentage Pharma Group International had 3 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 3 mentions for Ascentage Pharma Group International and 0 mentions for Centessa Pharmaceuticals. Ascentage Pharma Group International's average media sentiment score of 0.76 beat Centessa Pharmaceuticals' score of 0.00 indicating that Ascentage Pharma Group International is being referred to more favorably in the media.

Company Overall Sentiment
Ascentage Pharma Group International Positive
Centessa Pharmaceuticals Neutral

Summary

Ascentage Pharma Group International beats Centessa Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to CG Oncology?

Ascentage Pharma Group International (NASDAQ:AAPG) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

CG Oncology has lower revenue, but higher earnings than Ascentage Pharma Group International.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascentage Pharma Group International$82.10M22.58-$177.71MN/AN/A
CG Oncology$4.04M1,609.91-$160.99M-$2.33N/A

Ascentage Pharma Group International's return on equity of 0.00% beat CG Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Ascentage Pharma Group InternationalN/A N/A N/A
CG Oncology N/A -23.33%-22.24%

26.6% of CG Oncology shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ascentage Pharma Group International has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

Ascentage Pharma Group International presently has a consensus price target of $46.43, indicating a potential upside of 133.93%. CG Oncology has a consensus price target of $81.73, indicating a potential upside of 10.83%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts clearly believe Ascentage Pharma Group International is more favorable than CG Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20
CG Oncology
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.71

In the previous week, CG Oncology had 4 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 7 mentions for CG Oncology and 3 mentions for Ascentage Pharma Group International. CG Oncology's average media sentiment score of 0.77 beat Ascentage Pharma Group International's score of 0.76 indicating that CG Oncology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascentage Pharma Group International
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CG Oncology
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

CG Oncology beats Ascentage Pharma Group International on 8 of the 14 factors compared between the two stocks.

Get Ascentage Pharma Group International News Delivered to You Automatically

Sign up to receive the latest news and ratings for AAPG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AAPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AAPG vs. The Competition

Export
MetricAscentage Pharma Group InternationalMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.86B$3.66B$6.78B$12.59B
Dividend YieldN/A2.19%2.68%8.43%
P/E RatioN/A21.6327.1124.33
Price / Sales22.58326.37525.1092.04
Price / CashN/A143.6648.5959.39
Price / Book9.738.5010.826.30
Net Income-$177.71M$23.88M$3.59B$331.45M
7 Day Performance5.23%-3.22%-1.53%-0.08%
1 Month Performance14.46%5.42%2.75%-0.96%
1 Year Performance-46.01%51.50%28.40%19.89%

Ascentage Pharma Group International Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AAPG
Ascentage Pharma Group International
3.6976 of 5 stars		$19.84
+3.1%		$46.43
+134.0%		-46.9%$1.85B$82.10MN/A600
PTCT
PTC Therapeutics
3.327 of 5 stars		$83.31
flat		$91.36
+9.7%		+57.8%$6.91B$1.73BN/A1,410
COGT
Cogent Biosciences
1.7716 of 5 stars		$38.69
flat		$43.73
+13.0%		+247.2%$6.61BN/AN/A80
SRRK
Scholar Rock
1.9837 of 5 stars		$54.88
flat		$56.00
+2.0%		+39.4%$6.58BN/AN/A140
CNTA
Centessa Pharmaceuticals
0.8234 of 5 stars		$40.50
flat		$41.33
+2.1%		N/A$6.27BN/AN/A200

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AAPG) was last updated on 7/15/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel